Friday, January 6th, 2017
ONAMI Gap fund portfolio company TomegaVax has been acquired by newly formed Vir Biotechnology of San Francisco.
ONAMI Gap fund portfolio company TomegaVax has been acquired by newly formed Vir Biotechnology of San Francisco, following a $150M investment commitment by ARCH Ventures and undisclosed amounts from the Bill and Melinda Gates Foundation and other potential investors. Together with scientists at OHSU led by Klaus Frueh, TomegaVax successfully executed a $250,000 ONAMI Gap project to synthesize CMV vectored vaccines for human papillomavirus (HPV) and characterize their immune responses in Rhesus macaques. The new company will be headquartered in San Francisco but retain its laboratory operations and staff in Portland along with operations in Boston and San Francisco.